Aligos Therapeutics, Inc. (ALGS) Income Statement
ALGS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsALGS revenue and net income
Where ALGS's revenue goes
2025Each bar shows an amount and its share of revenue. ALGS kept −1,106.7% of revenue as net income.
ALGS profit margins
ALGS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −44.6% | −46.0% | — | — |
| Gross profit | −68.2% | −55.1% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALGS quarterly EPS vs estimates
Aligos Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-2.43).
ALGS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.9M | $15.5M | $13.9M | $4.4M | $0 | $0 | $0 |
| Cost of revenue | $930,000 | $2.6M | $3.1M | $3.7M | $104.2M | $3.3M | $2.3M | $1.3M |
| Gross profit | $1.3M | $3.9M | $15.5M | $13.9M | $4.4M | −$10.5M | −$2.3M | −$1.3M |
| Research & development | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M | $79.9M | $44.0M | $10.5M |
| Sales, general & admin | $20.7M | $22.8M | $30.6M | $26.4M | $28.5M | $17.9M | $10.0M | $3.2M |
| Total operating expenses | $89.2M | $93.1M | $103.7M | $111.5M | $132.7M | $97.8M | $54.0M | $13.7M |
| Operating income | −$88.0M | −$89.2M | −$88.1M | −$97.6M | −$128.3M | −$97.8M | −$54.0M | −$13.7M |
| Interest income | — | — | $1.2M | $1.6M | $132,000 | — | $1.6M | $163,000 |
| Interest expense | — | — | — | $1.6M | $132,000 | $10.5M | $1.9M | $0 |
| Income before taxes | −$23.9M | −$130.9M | −$86.9M | −$95.9M | −$128.2M | −$108.4M | −$52.2M | −$13.9M |
| Income taxes | $314,000 | $331,000 | $795,000 | $106,000 | $143,000 | $161,000 | $85,000 | −$272,000 |
| Net income | −$24.2M | −$131.2M | −$87.7M | −$96.0M | −$128.3M | −$108.5M | −$52.3M | −$13.9M |
| EBITDA | −$22.9M | −$128.3M | −$83.8M | −$93.9M | −$124.5M | −$94.5M | −$49.9M | −$12.4M |
| EPS (diluted) | −$1.36 | −$20.92 | −$34.47 | −$44.26 | −$58.64 | −$16.49 | −$2.38 | −$0.66 |
| Gross margin | 57.5% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating margin | −4,024.9% | −2,259.9% | −567.5% | −701.7% | −2,943.8% | — | — | — |
| Net margin | −1,106.7% | −3,326.0% | −564.6% | −690.6% | −2,944.1% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.8M | $2.8M | $169,000 | $741,000 | $965,000 | $311,000 | $629,000 | $1.3M | $1.1M | $986,000 | $2.7M | $3.2M |
| Cost of revenue | $0 | $0 | $257,000 | $0 | $259,000 | $0 | $671,000 | $0 | $610,000 | $674,000 | $775,000 | $681,000 |
| Gross profit | $27.8M | $2.8M | −$88,000 | $741,000 | $706,000 | $311,000 | $629,000 | $1.3M | $451,000 | $986,000 | $2.7M | $3.2M |
| Research & development | $24.1M | $23.4M | $17.0M | $23.9M | $14.0M | $14.5M | $16.0M | $16.8M | $21.1M | $16.4M | $22.3M | $15.9M |
| Sales, general & admin | $5.6M | $6.4M | $4.9M | $5.2M | $5.6M | $5.1M | $5.2M | $4.6M | $6.4M | $6.7M | $6.4M | $6.4M |
| Total operating expenses | $29.7M | $29.8M | $21.7M | $29.1M | $19.3M | $19.6M | $21.2M | $21.4M | $26.9M | $23.0M | $28.7M | $22.3M |
| Operating income | −$1.9M | −$26.9M | −$21.8M | −$28.4M | −$18.6M | −$19.2M | −$20.6M | −$20.1M | −$26.4M | −$22.0M | −$26.0M | −$19.1M |
| Interest income | $246,000 | $140,000 | — | $378,000 | $396,000 | $842,000 | — | $457,000 | $319,000 | $580,000 | $1.5M | $1.0M |
| Interest expense | — | — | — | — | — | — | — | — | — | $12.8M | $1.0M | — |
| Income before taxes | $1.3M | −$22.7M | −$19.9M | −$31.5M | −$15.7M | $43.1M | −$82.1M | −$19.2M | $5.2M | −$34.8M | −$27.9M | −$18.0M |
| Income taxes | $2.8M | $317,000 | $30,000 | $56,000 | $185,000 | $43,000 | $27,000 | $91,000 | $189,000 | $24,000 | −$30,000 | $29,000 |
| Net income | −$1.5M | −$23.0M | −$19.9M | −$31.5M | −$15.9M | $43.1M | −$82.2M | −$19.3M | $5.1M | −$34.9M | −$27.9M | −$18.0M |
| EBITDA | $1.6M | −$22.4M | −$19.1M | −$30.8M | −$15.4M | $43.6M | −$81.5M | −$18.5M | $5.9M | −$34.2M | −$27.1M | −$17.3M |
| EPS (diluted) | −$0.14 | −$2.21 | −$1.91 | −$3.04 | −$1.53 | $5.12 | −$13.10 | −$3.07 | $0.75 | −$5.50 | −$0.22 | −$10.25 |
| Gross margin | 100.0% | 100.0% | −52.1% | 100.0% | 73.2% | 100.0% | 100.0% | 100.0% | 42.5% | 100.0% | 100.0% | 100.0% |
| Operating margin | −6.8% | −951.6% | −12,907.7% | −3,827.4% | −1,924.0% | −6,187.5% | −3,269.2% | −1,586.4% | −2,489.5% | −2,235.9% | −969.7% | −588.8% |
| Net margin | −5.4% | −814.1% | −11,763.9% | −4,256.0% | −1,643.8% | 13,854.7% | −13,060.4% | −1,517.7% | 477.0% | −3,535.8% | −1,040.4% | −557.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALGS's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALGS financial results
In fiscal year 2025 (ended December 31, 2025), Aligos Therapeutics reported revenue of $2.2 million, down 44.6% from the year before. It had a net loss of $24.2 million, a net profit margin of −1,106.7%. Diluted earnings per share came to −$1.36.
See the ALGS stock overview for the latest quote and news, or the ALGS chart for price history and technical indicators.
ALGS income statement FAQ
What is Aligos Therapeutics's annual revenue?
Aligos Therapeutics reported total revenue of $2.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 44.6% from $3.9 million the previous year.
Is Aligos Therapeutics profitable?
No. Aligos Therapeutics reported a net loss of $24.2 million in fiscal 2025, a net profit margin of −1,106.7%; its operating margin was −4,024.9%.
What is Aligos Therapeutics's gross margin?
Aligos Therapeutics's gross margin was 57.5% in fiscal 2025: for every $100 of revenue, Aligos Therapeutics kept $57 after the direct cost of its products and services.
How much does Aligos Therapeutics spend on research and development?
Aligos Therapeutics spent $69.5 million on research and development in fiscal 2025, 3,177.2% of revenue.
What are Aligos Therapeutics's earnings per share?
Aligos Therapeutics earned $-1.36 per diluted share in fiscal 2025, compared with $-20.92 a year earlier.
When will Aligos Therapeutics report its next earnings?
Aligos Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Aligos Therapeutics's fiscal year end?
Aligos Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.